EVOK Stock Catalyst: Evoke Pharma Granted Notice of Allowance for GIMOTI Patent

Jul 8, 2025 · 3:59pm ET

The patent covers the use of GIMOTI in patients with moderate to severe gastroparesis.

Max move

+278.5%

High of day $9.88

Sparker timei

3:59pm ET

EVOK · Jul 8, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Evoke Pharma, Inc. (NASDAQ: EVOK) received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on July 09, 2025. The notice pertains to a U.S. patent application covering the use of GIMOTI in patients experiencing moderate to severe symptoms of gastroparesis.

The allowance signifies that the USPTO has determined the patent application meets the necessary requirements for patentability. This development strengthens Evoke Pharma's intellectual property portfolio for GIMOTI.

Evoke Pharma has a free float of 1,400,300 shares and 1,722,400 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time EVOK sparks.

Download Sniper App →

Catch the next EVOK-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →